Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations

Heart Failure Clinical Trial

— e-INCA  

Official title:

Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations Derived From Non Intrusive Sensors and Devices

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02411279
• Other study ID #: 6155
• Status: Recruiting
• Phase: N/A
• First received: March 17, 2015
• Last updated: May 18, 2017
• Start date: June 2015
• Est. completion date: September 2017

Study information

• Verified date: May 2017
• Source: University Hospital, Strasbourg, France
• Contact: ANDRES Emmanuel, MD, PhD
• Phone: 333 8811 5066
• Email: Emmanuel.ANDRES[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Heart failure (HF) is a serious chronic disease with frequent readmissions, some of which can be prevented by early action. The management of HF is complex: long, often difficult and costly. In France, nearly one million people suffer from HF and 120,000 new cases are diagnosed every year. With the aging population, this number will continue to evolve and become a real public health problem. Within 10 to 20 years ahead, WHO projects that heart failure in either the 3 most common diseases in industrialized countries.

The objective of the project is to test an intelligent platform for monitoring at home, using non-intrusive sensors, patients with heart failure, particularly those with stage II and III NYHA. It will assist the medical automating the processing of information from these sensors to detect and report an early stage risk situations.

Patient monitoring, by a system of telemedicine tools associated with motivation and education helps significantly reduce the number of days of hospitalization becomes important when the patient is hospitalized for acute HF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Population with heart failure stage II and III

Exclusion Criteria:

• Population whose age is less than 18 years

Related Conditions & MeSH terms

• Heart Failure

Intervention

Other:
• Equiped group with telemedicine systems

Locations

Country	Name	City	State
France	Service de Médecine Interne, diabète et maladies métaboliques - Médicale B	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anticipation and detection of heart failure with automatic treatment of information derived from non intrusive sensors and devices		patient's medical data will be controlled remotely by health professional for the duration of hospital stay, up to 1 year]